Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0A6CQ
|
||||
| Former ID |
DAP001396
|
||||
| Drug Name |
Levobetaxolol
|
||||
| Synonyms |
Levobetaxolol [INN]; Betaxon (TN); (-)-Betaxolol; (2S)-1-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-(propan-2-ylamino)propan-2-ol; (2S)-1-{4-[2-(cyclopropylmethoxy)ethyl]phenoxy}-3-(propan-2-ylamino)propan-2-ol; (2s)-1-{4-[2-(cyclopropylmethoxy)ethyl]phenoxy}-3-(isopropylamino)propan-2-ol; (S)-(-)-Betaxolol; (S)-1-(isopropylamino)-3-[p-(cyclopropylmethoxyethyl)phenoxy]-2-propanol; (S)-Betaxolol
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Chronic open-angle glaucoma; Ocular hypertension [ICD10:H40] | Approved | [1] | ||
| Therapeutic Class |
Cardiotonic Agents
|
||||
| Company |
Alcon Pharmaceuticals Ltd
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C18H29NO3
|
||||
| InChI |
InChI=1S/C18H29NO3/c1-14(2)19-11-17(20)13-22-18-7-5-15(6-8-18)9-10-21-12-16-3-4-16/h5-8,14,16-17,19-20H,3-4,9-13H2,1-2H3/t17-/m0/s1
|
||||
| InChIKey |
NWIUTZDMDHAVTP-KRWDZBQOSA-N
|
||||
| CAS Number |
CAS 116209-55-3
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Beta-1 adrenergic receptor | Target Info | Antagonist | [2] | |
| KEGG Pathway | Calcium signaling pathway | ||||
| cGMP-PKG signaling pathway | |||||
| cAMP signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Endocytosis | |||||
| Adrenergic signaling in cardiomyocytes | |||||
| Gap junction | |||||
| Salivary secretion | |||||
| Dilated cardiomyopathy | |||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Beta1 adrenergic receptor signaling pathway | |||||
| PathWhiz Pathway | Muscle/Heart Contraction | ||||
| Reactome | Adrenoceptors | ||||
| G alpha (s) signalling events | |||||
| WikiPathways | Monoamine GPCRs | ||||
| Calcium Regulation in the Cardiac Cell | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| Endothelin Pathways | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | ||||
| REF 2 | Binding affinities of ocular hypotensive beta-blockers levobetaxolol, levobunolol, and timolol at endogenous guinea pig beta-adrenoceptors. J Ocul Pharmacol Ther. 2004 Apr;20(2):93-9. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.